Disposition of 6564 shares by Heather Prichard of Humacyte subject to Rule 16b-3

HUMAW Stock  USD 1.50  0.09  5.66%   
Slightly above 62% of Humacyte's investor base is looking to short. The analysis of the overall investor sentiment regarding Humacyte suggests that many traders are alarmed. Humacyte's investing sentiment can be driven by a variety of factors including economic data, Humacyte's earnings reports, geopolitical events, and overall market trends.
  
Filed transaction by Humacyte Officer Chief Operating Officer. Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3

Read at macroaxis.com
Humacyte insider trading alert for disposition of stock options (right to buy) by Heather Prichard, Officer: Chief Operating Officer, on 22nd of March 2024. This event was filed by Humacyte with SEC on 2022-12-12. Statement of changes in beneficial ownership - SEC Form 4

Cash Flow Correlation

Humacyte's cash-flow correlation analysis can be used to evaluate the unsystematic risk during the given period. It also helps investors identify the Humacyte's relationships between the major components of the statement of changes in financial position and other commonly used cash-related accounts. When such correlations are discovered, they may help managers and analysts to enhance performance or determine appealing investment opportunities.
Click cells to compare fundamentals

Humacyte Fundamental Analysis

We analyze Humacyte's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Humacyte using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Humacyte based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.

Number Of Employees

Number Of Employees Comparative Analysis

Humacyte is currently under evaluation in number of employees category among its peers. Number of Employees shows the total number of permanent full time and part time employees working for a given company and processed through its payroll.

Humacyte Potential Pair-trading

One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Humacyte stock to make a market-neutral strategy. Peer analysis of Humacyte could also be used in its relative valuation, which is a method of valuing Humacyte by comparing valuation metrics with similar companies.

Additional Tools for Humacyte Stock Analysis

When running Humacyte's price analysis, check to measure Humacyte's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Humacyte is operating at the current time. Most of Humacyte's value examination focuses on studying past and present price action to predict the probability of Humacyte's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Humacyte's price. Additionally, you may evaluate how the addition of Humacyte to your portfolios can decrease your overall portfolio volatility.